Suppr超能文献

印度北部非酒精性慢性肝病中丙型肝炎病毒及双重感染(乙型和丙型肝炎病毒)的高血清流行率

High seroprevalence of hepatitis C virus and dual infection (hepatitis B and C virus) in non-alcoholic chronic liver disease in north India.

作者信息

Sood A, Sidhu S S, Midha V, Jyoti D

机构信息

Dept of Medicine, Dayanand Medical College and Hospital, Ludhiana, India.

出版信息

J Assoc Physicians India. 1999 Feb;47(2):205-8.

Abstract

BACKGROUND

There are conflicting reports on the prevalence of hepatitis B and C virus (HBV and HCV) mediated chronic liver disease (CLD) in India.

AIM

To study the prevalence of HBV and HCV associated in CLD in north India.

MATERIAL AND METHODS

Eighty five patients (66 males, 19 females; age range 16-70 years) with unequivocal CLD were analysed. CLD patients with nonviral aetiologies were excluded. All sera were tested for anti-HCV by EIA (third generation), HBsAg, IgM and IgG anti-HBc, HBeAg/Anti-HBe by EIA (Abbott Diagnostics, IL). Positive anti-HCV results were confirmed by RIBA-II assay.

RESULTS

Sixteen (18.8%), 22 (25.9%) and 21 (24.7%) patients had HBV, HCV and HBV + HCV infection, respectively. Twenty six (30.6%) CLD patients had no viral markers.

CONCLUSION

HCV is emerging as an important cause of CLD in India. Dual infection (HBV + HCV) is seen in 25% patients. Dual infection influences the prognosis and response rates to interferon therapy.

摘要

背景

关于印度乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)介导的慢性肝病(CLD)的患病率,存在相互矛盾的报道。

目的

研究印度北部CLD中HBV和HCV的患病率。

材料与方法

分析了85例明确诊断为CLD的患者(66例男性,19例女性;年龄范围16 - 70岁)。排除非病毒病因的CLD患者。所有血清均通过酶免疫测定法(第三代)检测抗HCV、HBsAg、IgM和IgG抗HBc、HBeAg/抗HBe(雅培诊断公司,伊利诺伊州)。抗HCV阳性结果通过重组免疫印迹法(RIBA-II)进行确认。

结果

分别有16例(18.8%)、22例(25.9%)和21例(24.7%)患者感染了HBV、HCV和HBV + HCV。26例(30.6%)CLD患者没有病毒标志物。

结论

HCV正在成为印度CLD的一个重要病因。25%的患者存在双重感染(HBV + HCV)。双重感染会影响干扰素治疗的预后和有效率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验